Febrile Neutropenia

What you need to know !





2017 Community Cancer Care Educational Conference

Presenter Disclosure

- Faculty: Gisele Sarbacher
- Relationships with commercial interests: NONE



Mitigating Potential Bias

• NONE



Learning Objectives

At the end of this workshop, participants will be able to:

- Define febrile neutropenia, understand its urgency, and identify populations at risk
- Utilize the new febrile neutropenia (FNE) resources in the identification and management of patients with FNE



What is Febrile Neutropenia?

Fever:

 A single oral temperature of 38.3'C (101'F), or greater than 38'C (100.4'F) lasting at least 1 hour, or greater than 38'C (100.4'F) documented at least twice over a 12 hour period.

<u>Neutropenia</u>:

"Severe" neutropenia is defined by an absolute neutrophil count (ANC) < 0.5 x 10⁹/L, or ANC <1.0 x 10⁹/L and a predicted decline of the ANC to < 0.5 x 10⁹/L over the next 48 hours

(Neutropenia Protocol, 2017 CCMB Infection Prevention and Control Manual)



Who is at Risk?

- Older age, female sex
- Poor nutritional status
- Pre-existing neutropenia
- Bone marrow failure secondary to:
 - Prior cytotoxic therapy
 - Prior radiation therapy
- Marrow invasion by cancer
- Open wounds, or active tissue infection
- Active co-morbid conditions
- Hematological malignancy
- Impaired immune function associated with an absolute lymphocyte count < 0.5 x 10 ⁹/L



Why the Urgency?

- Patients with cytotoxic therapy-induced severe neutropenia are a risk for potentially life-threatening invasive bacterial infections
- Delayed and/or inappropriate treatment of neutropenic fever syndrome is associated with increased morbidity and mortality
- □ Timely intervention may be life-saving




Timeline of ONE HOUR for assessment and initial antibacterial therapy is critical





Resources Developed through Collaborative Efforts









events.

Work up

lectate

Consider

Definitions

Telephone Triage

Assessment and Workup

ASK:

Date of last CBC

Ossaturation) • Focal pain referable to:

o nose (e.g. sinusitis)

catheter

Infaction

Algorithm

critical to successful management

Pre-existing neutropenia

Prior radiation therapy

History of a neutropenic fever syndrome

Bone marrow failure secondary to:

o Prior cytotoxic chemotherapy

Open wounds or active thsue infection

Impaired immune function associated with an absolute

lymphocyte count (ALC) less than 0.5 x 10⁴/L

 Current medications, including antimicrobial therapy Adverse drug reaction history. ALLERGIES

If patient has taken acetaminophen/Tylenol*

If severe symptoms and/or change in mental status:

Full vital signs (temperature, pulse, respiration, blood pressure,

o eyes (e.g. conjunctivitis, periorbital cellulitis)

mouth (e.g. stomatitis and oral ulcers)
 throat (e.g. oral mucositis, gingivitis, pharyngitis,

· Symptoms that may suggest a lower respiratory focus:

· Focal abdominal pain and diarrhea may suggest an

· Presence of central venous access device (CVAD), or peripheral venous

· Focal skin or soft tissue swelling, tenderness, and erythema, especially

anatomically related to a CVAD may suggest a cellulitis or CVL-related

o ears (e.g. otitis externs or media)

parapharyngeal space infection)

Intra-abdominal sepsis syndrome

Use MASCC Risk Index Score

CCMB Department of Nursing May 11, 2017

o repid or deep breathing (e.g. dyspnes)

o chest pain (e.g. pleuritic inflammation) o cough or wheezing

RISK FACTORS


SEVERE NEUTROPENIA - Absolute Neutrophil Count (ANC) less than 0.5 x 10⁹/L

· If patient is receiving hematopoletic growth factors (e.g. Neupogen*, filgrastim)

NURSING ALGORITHM - NEUTROPENIC FEVER

INITIAL ASSESSMENT, WORKUP AND TREATMENT

ADULTS WITH CANCER - AMBULATORY SETTING



Neutropenic Fever - Initial Assessment, Workup and Treatment, Adults with Cancer - Ambulatory Setting (SEE OVER) References
1. Scalin, P., Coyle, V., Kette, P. et al. 2018. Guidelines for the management of occology/haematology adult patients [>18] with re-stropenic septis. Northern initiand Canoe
1. Scalin, P., Coyle, V., Kette, P. et al. 2018. Guidelines for the management of occology/haematology adult patients [>18] with re-stropenic septis. Northern initiand Canoe
2. Scalin, P., Coyle, V., Kette, P. et al. 2018. Guidelines for the management of occology/haematology adult patients [>18] with re-stropenic septis. Northern initiand Canoe
2. Scalin, P., Coyle, V., Kette, P. et al. 2018. Guidelines for the management of occology/haematology adult patients [>18] with re-stropenic septis. Northern initiand Canoe
2. Scalin, P., Coyle, V., Kette, P. et al. 2018. Guidelines for the management of occology/haematology adult patients [>18] with re-stropenic septis. Northern initiand Canoe
2. Scalin, P., Coyle, V., Kette, P. et al. 2018. Guidelines for the management of occology/haematology adult patients [>18] with re-stropenic septis. Northern initiand Canoe
2. Scalin, P., Coyle, V., Kette, P. et al. 2018. Guidelines for the management of occology/haematology adult patients [>18] with re-stropenic septis. Northern initiand Canoe
2. Scalin, P. Coyle, V., Kette, P. et al. 2018. Guidelines for the management of occology/haematology adult patients [>18] with re-stropenic septis. Northern initiand Canoe
2. Scalin, P. Coyle, V., Kette, P. et al. 2018. Guidelines for the management of occology/haematology adult patients [>18] with re-stropenic septis. Scalin, P. et al. 2018. Guidelines for the management of occology/haematology adult patients [>18] with re-stropenic septis. Scalin, P. et al. 2018. Guidelines for the management of occology. Scalin, P. et al. 2018. Guidelines for the management of occology. Scalin, P. et al. 2018. Guidelines for the management of occology. Scalin, P. et al. 2018. Guidelines for the management of occology. Scalin, P. et al. 2018. Guidelines for the management of occology. Scalin, P. et al. 2018. Guidelines



Patient Information Handout

Patient Information Sheet—Neutropenia

(low white blood cell count)

What is Neutropenia?

Neutropenia occurs when a certain type of white blood cell-called neutrophils-are low. These white blood cells, which are made in your bone marrow, are important to fight infection and keep you healthy. When the number of neutrophils in the blood becomes low, your body might find it harder to fight infection.

This information sheet will help you to know what to do if you feel unwell, with or without a fever.

How will I know if I have Neutropenia?

Most people who have neutropenia do not know it. They do not have any symptoms and do not feel sick. Having a blood test is the only way to confirm if you have neutropenia

There are signs that should alert you to possible infection:

1. Fever - A fever is a body temperature above 38°C or 100.4°F. It is most accurate to take your temperature with a digital thermometer.

2. Any of the following symptoms with or without a fever -

- Chills/shaking
- Having to pass small amounts of urine

 Flu-like symptoms such as body
- New cough
- often
- Shortness of breath
- Sore throat
- Mouth sores
- Burning feeling when you pass urine
 Pain, redness or swelling on Urine that is strong-smelling or cloudy (not clear) or red or pink in color
- Abdominal (belly) pain Diarrhea, nausea, vomiting

What causes Neutropenia?

Many things can cause neutropenia but the most common causes are:

Chemotherapy - Chemotherapy can affect the bone marrow and slow down how many white blood cells are being made. This can cause neutropenia.

Radiation Therapy - Large bones like the breast bone or hip bones have more bone marrow in them. Radiation to these bones can affect the bone marrow and slow down how many white blood cells are being made. This can cause neutropenia. If you are having chemotherapy and radiation together, this may increase the risk of neutropenia.

Cancer or Blood Disorders - Some types of cancer or blood disorders cause low white cells without having any treatment

How might having Neutropenia affect my treatment?

Your Cancer Team may decide to delay your treatment or lower the dose to keep you as healthy as possible during treatment. The decision will be based on YOUR treatment plan and YOUR health

CCMB Department of Nursing August 15, 2017





DO wash your hands

- · Always before eating and after going to the bathroom
- After contact with pets
- · Carry hand sanitizer with you in case you don't have access to soap and water
- DO bathe or shower daily and change clothes daily
- DO try to prevent scrapes, scratches or injury to skin. This includes mouth, penis, vagina and anus

DO check with your Cancer Team

- · Before having any immunizations
- · Before having dental work or teeth cleaning. Let your dentist know that you
- are having cancer treatment
- · About sexual activity when you are neutropenic
- About avoiding large crowds

DON'T go near anyone who has a cold, flu, diarrhea or other contagious illnesses (e.g. chicken pox, shingles)

DON'T take Tylenol regularly unless your oncologist or hematologist has said this is OK. Tylenol will mask a fever.

What should I do if my temperature is greater than 38°C/100.4°F or if I become unwell?

If you feel very unwell, go to your nearest emergency department.


Bring all the medications you are taking with you.

Tell the Emergency Department staff:

- the name of your cancer or blood disorder
- the type of treatment you are on—it is helpful to know the name of any cancer drug.
- the first day of your most recent treatment (chemotherapy and/or radiation therapy)

Get the right medical help as soon as possible

If you have questions or concerns:





TALK WITH

YOUR

CANCER TEAM

ABOUT

PREVENTING

INFECTION!

Neutropenia with symptoms or fever can be life threatening. Get medical help right away!

aches and feeling tired skin, especially around an IV or

a cut or wound

PICC line or around wounds

Green or yellow drainage from

Pre-printed Order Sets

Institution or RHA LOGO	
PHYSICIAN'S ORDER SHEET	
FEBRILE NEUTROPENIA ORD	ERS

Unwell Cancer Patients (with or without a fever) who have received systemic anti-cancer therapy in previous 6 weeks, with anticipated absolute neutrophil count < 0.5 x 10⁹/L, and suspected infection

DRAFT

RECORD NO.

LOC'N

Administration of initial empirical antibacterial therapy within 60 minutes of suspicion of a neutropenic fever (sepsis) syndrome

DATE PATIENT

DOB

PROV HC#

DOCTOR

CLINIC/UNIT

rug Allergies →	ORDER TRANSCRIBED AND ACTIVATED		DATE: TIME: Patient's Height Patient's Weight
R MEDICATION ORDERS TO BE INITIATED OR DISCONTINUED	0	TEST DONE	GENERAL ORDERS PAGE 1 OF 2
ATE:TIME: Intral Therapy ML bolus over hours I Normal Saline intravenously ML/hr I Orrygen L /min nasal prongs Iteh-Risk Patients			CBC, electrolytes, glucose, urea, creatinine CHOROUS blood gases Lactate INR, Prochrombin Tune AST, ALT, LDH, GGT, ALP, Total Blinubin Blood Culture <u>before</u> antibiotic administration from 2.1 peripheral sites and all parenteral lines as follows: 0. One each: scrobic and an aerobic blood culture
ngi-nois Faulenta MASCC less than 21, and/or other criteria – Features p.2) Piperacillin/tazobactam 4.5 grams intravenously every 8 hours – first dose within 60 minutes after arrival			bottle from a peripheral site, and One aerobic blood culture bottle from each lumen of a multi-lumen central venous catheter (CVC) Where there is no CVC, obtain blood cultures from
Methicillin-resistant Staphylococcus auraus (MRSA) risk factors, colonization, skin/soft tissue infection) consider adding: j Vancomycinmilligrams (15 mg/kg/dose) intravenously every 12 hours			≥ 2 peripheral sites □ Urinalysis and urine culture □ Chest radiograph □ Electrocardiogram □ Other:
Vancomycin-resistant Entarococcus (VRE) colonization consider adding: Linezolid 600 milligrams intravenously every 12 hours isuspected Extended spectrum Beta Lactamase (ESBL) – producing gram- egaive bacillary infection: Meropenem 1 gram intravenously every 8 hours			Vital signs every 30 minutes Document height and weight Complete risk stratification (see p.2) If "Severe sepsis / Septic shock syndrome" – add Sepsis Order Sev
− first dose within 60 minutes after arrival severe sepsis/septic shock consider adding: Gentamicin or □ fobramycinmilligrams (7 mg/kg) intravenously daily, dose adjusted for serum creatinine and trough levels peracillin/tasobactam, meropenem, lineabid are restricted drugs. going prescription requires mandatory consultation with Infectious			Consult MICU, if severe sepsis / septic shock Consult Medicine Consult Medicine Consult Medical Oncology, Radiation Oncology, Adult Hematology, or Leukemia / Bone Marrow Transplant Service (circle desired service) Consult Infectious Diseases Services
sesses Services. 			Low-Risk Patients Following work-up and initial empirical antibacterial therapy: Observe for 4 hours with stable vital signs Phone oncology on call to make aware of discharge (see p.2) Ensure follow-up within 48 hours
HTSICIAITS GNATURE: MD			TRANSCHIBED: REVIEWER:
NTED ME: GENERIC EQUIVALENT AUTHORIZED MD			FAXED DATE: TIME: INITIALS:



FEBRILE NEUTROPENIA ORDERS

Unwell Cancer Patients (with or without a fever) who have received systemic anti-cancer therapy in previous 6 weeks, with anticipated absolute neutrophil count < 0.5 x 10⁹/L, and suspected infection

CLINIC/UNIT

RECORD NO.

DRAFT

LOC'N

Administration of initial empirical antibacterial therapy within <u>60 minutes</u> of suspicion of a neutropenic fever (sepsis) syndrome

DATE

PATIENT

DOB

PROV HC#

DOCTOR

These orders are to be used as a guideline and do not replace sound clinical judgment and professional practice standards. Patient allergy and contraindications must be considered when completing these orders. Standar dores: If not in acrement with an order, cross out and initial. Deleviers a check (*) for activation.							
Drug Allergies →	ORDER TRANSCRIBED AND ACTIVATED		DATE: TIME: Patient's Height Patient's Weight				
R MEDICATION ORDERS	0	TEST	GENERAL ORDERS PAGE 2 OF 2				
DATE: TIME: Penicillin Allergy Substitutions Inmediate-type (less than 1 hour onset) or accelerated-type (less than 72 hours onset) reactions: ii) High-risk patients ii) Meropenem 1 gram intravenously every 8 hours (preferred) OR Ciprofloxacin 400 milligrams intravenously every 12 hours (only if a fluoroquinolone was not used as prophylaxis) plus Vancomycinmilligrams orally every 8 hours (preferred) OR Ciprofloxacin 750 milligrams orally every 8 hours (preferred) OR Mourifloxacin 400 milligrams orally every 2 hours (preferred) OR Mourifloxacin 750 milligrams orally every 2 hours (preforeacin 750 milligrams orally every 2 hours (preferred) OR Mourifloxacin 400 milligrams orally every 2 hours (preferred) OR Mourifloxacin 750 milligrams orally every 2 hours (preferred) OR Cepacidime 2 grams intravenously every 8 hours (Preferred) OR Cefasidime 2 grams intravenously every 8 hours (Preferred) OR Cefasidime 2 grams intravenously every 8 hours plus Vancomycinmilligrams orally every 12 hours plus Vancomycinmilligrams orally every 12 hours plus Vancomycin =milligrams orally every 12 hours plus Vancomycin =			High-Risk Features for medical complications requiring admission (MASCC less than 21) Profound neutropenia XNC less than 100mm ³ following cytotoxic chemotherapy Anticipated sever neutropenia preter than 7 days Hypotension (SP = 80 mmHg, or MAP < 70 mmHg)				
PHYSICIAN'S SIGNATURE: MD			TRANSCRIPTO REVERGE				
PRINTED MARKE: GENERIC EQUIVALENT AUTHORIZED MD			FAXED DATE: TIME: INITIALS:				

AUTHORIZED BY:

P PI N

> DATE: REVIEW PENDING CPGI Updated: May 11, 2017



2017 Community Cancer Care Educational Conference

Neutropenia Protocol – Identification and Management of Neutropenic Fever Syndrome

۲	Car	ncerCareManitoba			
	Actio		REVENTION AND CONTROL		
		POLICIES, PROCEDURES, GUIL	DELINES AND PROTOCOLS		
PRC	тосо	L TITLE: Neutropenia Protocol – Identificatio Neutropenic Fever Syndromes	on and Management of		
SEC	TION:	Infection Control PROTOCOL NO.: 12.500	APPROVED BY THE		
		Services muary 6, 2012 PAGE: 1 of 22	PRESIDENT AND CEO, CCMB Original signed by		
		ew: May 8, 2017 PAGE: 1 of 22	Dr. S. Navaratnam		
			L		
1.0	BACK	(GROUND:			
	1.1	Patients with cytotoxic therapy-induced severe neurisk for potentially life-threatening invasive bacteria			
	1.2	Risk factors for developing a neutropenic fever syn female sex, marrow invasion by cancer, reduced g status, integumental damage, hematological malig conditions. ^{3,4}	ranulopoiesis, poor nutritional		
	1.3	Delayed and/or inappropriate treatment of neutropenic fever syndromes is associated with increased morbidity and mortality. ⁵			
	1.4	Successful management of neutropenic fever syno time-sensitive. ⁶ Timely intervention may be life-say			
	1.5	Rapid triage to recognize and prioritize neutropeni emergent initial empirical anti-bacterial therapy is o such events. ⁸			
2.0	PURP	POSE:			
	2.1	To provide healthcare providers at CancerCare Ma Regional Health Authority (WRHA), and the provin with standardized guidelines for the rapid triage, as management of new onset of suspected sepsis syn fever and neutropenia.	cial regional health authorities ssessment, and initial		
	2.2	To provide nursing and medical staff with a timelin the provision of triage, "sepsis syndrome" assessm bacterial treatment services for suspected neutrop accordance with the time-dependent CTAS Level framework should allow the clinician to make an in therapeutic plan based upon the patient history, vii examination in the absence of laboratory test result	nent, and initial empirical anti- enic sepsis syndromes in II (Emergent) standard. This itial clinical assessment and tal signs, and clinical		
	2.3	To provide healthcare providers with a guideline for neutropenic sepsis syndromes over the subsequer administration of initial empirical anti-bacterial then	nt 72 to 120 hours from the		



Key Messages

Time to Medical Assessment

If a patient receiving chemotherapy presents with a fever, medical assessment is required within <u>15</u>
 <u>minutes</u> of presentation to facility.

Assume Febrile Neutropenia

- O Don't Wait for Blood Work Results
- Begin Assessment & Interventions Follow the Neutropenic Nursing Algorithm
- Administer first dose of anti-bacterial therapy within 60 minutes



References

7.0 <u>REFERENCES</u>:

- Bow EJ, Wingard JR, Bowden RA: Infectious complications in patients receiving cytotoxic therapy for acute leukemia: History, background and approaches to managment, Management of Infection in Oncology Patients. London, Martin Dunitz, 2003, pp 71-104
- 2. Bow EJ: Infection in neutropenic patients with cancer. Crit Care Clin 29:411-41, 2013
- Bow EJ: The Diagnostic Approach to the Febrile Neutropaenic Patient: Clinical Considerations, in Maschmeyer G, Rolston, K.V.I. (ed): Infections in Hematology. Berlin, Heidelberg, Springer-Verlag, 2015, pp 91-111
- Bow EJ: Approach to Infection in Patients Receiving Cytotoxic Chemotherapy for Malignancy, in Hall JB, Schmidt GA, Kress JP (eds): Principles of Critical Care (ed 4th). New York, McGraw-Hill, 2015, pp 600-625
- Okera M, Chan S, Dernede U, et al: A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings. Br J Cancer 104:407-12, 2011
- Richardson S, Pallot D, Hughes T, et al: Improving management of neutropenic sepsis in the emergency department. Br J Haematol 144:617-8, 2009
- Gaieski DF, Mikkelsen ME, Band RA, et al: Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 38:1045-53, 2010
- Flowers CR, Seidenfeld J, Bow EJ, et al: Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: american society of clinical oncology clinical practice guideline. J Clin Oncol 31:794-810, 2013
- Freifeld AG, Bow EJ, Sepkowitz KA, et al: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52:e56-93, 2011

